- Home
- ASUR vs IMMP Comparison
ASUR vs IMMP Comparison
Compare ASUR & IMMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ASUR
- IMMP
- Stock Information
- Founded
- ASUR 1985
- IMMP 1987
- Country
- ASUR United States
- IMMP Australia
- Employees
- ASUR N/A
- IMMP N/A
- Industry
- ASUR EDP Services
- IMMP Biotechnology: Pharmaceutical Preparations
- Sector
- ASUR Technology
- IMMP Health Care
- Exchange
- ASUR Nasdaq
- IMMP Nasdaq
- Market Cap
- ASUR 297.7M
- IMMP 304.0M
- IPO Year
- ASUR 1992
- IMMP N/A
- Fundamental
- Price
- ASUR $9.53
- IMMP $1.78
- Analyst Decision
- ASUR Strong Buy
- IMMP Buy
- Analyst Count
- ASUR 8
- IMMP 2
- Target Price
- ASUR $13.25
- IMMP $8.50
- AVG Volume (30 Days)
- ASUR 95.4K
- IMMP 82.5K
- Earning Date
- ASUR 03-06-2025
- IMMP 03-25-2025
- Dividend Yield
- ASUR N/A
- IMMP N/A
- EPS Growth
- ASUR N/A
- IMMP N/A
- EPS
- ASUR N/A
- IMMP N/A
- Revenue
- ASUR $119,792,000.00
- IMMP $3,019,249.00
- Revenue This Year
- ASUR $14.65
- IMMP N/A
- Revenue Next Year
- ASUR $9.05
- IMMP $20.28
- P/E Ratio
- ASUR N/A
- IMMP N/A
- Revenue Growth
- ASUR 0.60
- IMMP 24.11
- 52 Week Low
- ASUR $6.89
- IMMP $1.65
- 52 Week High
- ASUR $12.74
- IMMP $3.34
- Technical
- Relative Strength Index (RSI)
- ASUR 38.29
- IMMP 41.69
- Support Level
- ASUR $9.00
- IMMP $1.65
- Resistance Level
- ASUR $9.66
- IMMP $1.88
- Average True Range (ATR)
- ASUR 0.61
- IMMP 0.10
- MACD
- ASUR -0.14
- IMMP -0.01
- Stochastic Oscillator
- ASUR 20.70
- IMMP 41.94
About ASUR Asure Software Inc
Asure Software Inc is a provider of cloud-based Human Capital Management (HCM) solutions delivered as Software-as-a-Service (SaaS). It facilitates small and mid-sized businesses (SMBs) to develop their Human Capital to get to the next level, stay compliant, and allocate their time, money and technology toward growth. The company's HCM suite, named AsureHCM, includes cloud-based Payroll and Tax, HR, a Time and Attendance software. Its HR services range from HR projects to outsourcing payroll to HR consulting services. The firm sells its HCM products majorly in the United States.
About IMMP Immutep Limited
Immutep Ltd is a globally active biotechnology company developing immunotherapy products for cancer and autoimmune diseases. Its main product is IMP321, which involves clinical development for the treatment of cancer indications. The company is also focused on the development of other products, which include IMP701, which is a blocking anti-LAG-3 antibody for cancer and is in Phase I of its clinical trials, and CVac, which is a personalized immunocellular therapeutic investigated for the treatment of epithelial cancer. Geographically all the business activity of the firm is functioned through the region of Australia.